Vinn,
Excellent post and what a progressive coy to be partnership with.
TEVA's no 1 selling drug is its $3 billion multiple sclerosis(MS) drug Copaxone which currently makes up 21% of sales(coming off patent in 2013). So TEVAs acquisition of CEPH now has the merged entity @ $20bn - talk about forward planning by this super Global Pharma.
And if the Cardio Franshise wanst enough, just to make sure that MSB retains its NO 1 'sweetheart' title within the TEVA family, the Blaster is looking at developing an MS application as part of its Intravenous Program /Francshise ( page 5 annual report).
Great 2012 coming on !
Cheers to all holders.
Vinn,Excellent post and what a progressive coy to be partnership...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |